Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Depression in MCI or Early Alzheimer's Disease
NCT04123314Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Mar 2021
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Johns Hopkins University. Primary endpoint: Cornell Scale for Depression in Dementia. Started Mar 2021; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04123314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123314.